The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Trevi Therapeutics Inc (NASDAQ: TRVI) closed at $10.64 in the last session, down -2.03% from day before closing price of $10.86. In other words, the price has decreased by -$2.03 from its previous closing price. On the day, 1.76 million shares were traded. TRVI stock price reached its highest trading level at $10.78 during the session, while it also had its lowest trading level at $10.28.
Ratios:
We take a closer look at TRVI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 22.42 and its Current Ratio is at 22.42. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on August 21, 2025, initiated with a Overweight rating and assigned the stock a target price of $18.
On July 01, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
On May 28, 2025, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $21.H.C. Wainwright initiated its Buy rating on May 28, 2025, with a $21 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Delfini Lisa bought 108,650 shares for $9.50 per share.
Delfini Lisa bought 40,000 shares of TRVI for $386,716 on Oct 03 ’25. On Aug 27 ’25, another insider, Delfini Lisa, who serves as the Officer of the company, bought 312,855 shares for $8.09 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TRVI now has a Market Capitalization of 1295705728 and an Enterprise Value of 1092711680.
Stock Price History:
The Beta on a monthly basis for TRVI is 0.86, which has changed by 2.7448275 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, TRVI has reached a high of $11.83, while it has fallen to a 52-week low of $2.36. The 50-Day Moving Average of the stock is 14.21%, while the 200-Day Moving Average is calculated to be 54.94%.
Shares Statistics:
According to the various share statistics, TRVI traded on average about 2.11M shares per day over the past 3-months and 1329040 shares per day over the past 10 days. A total of 121.78M shares are outstanding, with a floating share count of 80.73M. Insiders hold about 33.70% of the company’s shares, while institutions hold 60.96% stake in the company. Shares short for TRVI as of 1760486400 were 14589302 with a Short Ratio of 6.92, compared to 1757894400 on 12090295. Therefore, it implies a Short% of Shares Outstanding of 14589302 and a Short% of Float of 13.88.
Earnings Estimates
Investors are eagerly awaiting the insights provided by 8.0 analysts currently analyzing and rating the stock of Trevi Therapeutics Inc (TRVI).The consensus estimate for the next quarter is -$0.11, with high estimates of -$0.1 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.38 and -$0.44 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$0.49, with 8.0 analysts recommending between -$0.24 and -$0.65.
